Technology | November 03, 2014

Elekta receives FDA 510(k) clearance for Response automatic gating for prostate cancer cases


November 3, 2014 — Elekta's Clarity 4-D prostate monitoring system can now automatically interrupt, or "gate," the radiation beam when it detects that the prostate has moved out of position. Clarity 4-D Monitoring software has enabled doctors to continuously visualize the prostate's precise location during radiation therapy. U.S. Food and Drug Administration (FDA) 510(k) clearance for Clarity to be used with Elekta's Response gating interface will give United States physicians the potential to further safeguard the patient's normal tissues from overexposure to radiation during prostate radiotherapy. The feature is available as an option with Elekta's advanced Versa HD radiation therapy treatment system.

Reliably localizing the prostate is critical during precision radiotherapy, as dose is being constantly delivered to its assumed location even though the prostate's position may be changing due to pressure from surrounding anatomy such as the bladder or rectum.

"The Clarity system permits clinicians to set the amount of prostate movement allowable over a given period, for example, three or five millimeters for a five-second period, depending on the dose rate and other factors," explains Tony Falco, senior vice president, Elekta Software. "When Clarity detects anything over this limit, the treatment is automatically paused to allow clinicians to correct for the motion. This could be especially important for clinicians pursuing advanced prostate protocols, such as reduced margin hypofractionated therapy or stereotactic body radiation therapy [SBRT]." 

Automated beam gating with Response will also help streamline prostate radiotherapy workflow by removing the human reaction time to prostate position alerts, he adds.

For more information: www.elekta.com

Related Content

News | Lung Imaging

August 10, 2022 — Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 ...

Time August 10, 2022
arrow
News | Breast Imaging

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — Representatives from the Diagnostics Working Group of the IASLC Early Detection and Screening Committee ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill ...

Time August 08, 2022
arrow
News | Proton Therapy

August 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, Fred ...

Time August 05, 2022
arrow
Feature | Oncology Information Management Systems (OIMS)

August 2, 2022 — The oncology information systems market is projected to be worth $2.59 Bn by 2022 and is expected to ...

Time August 02, 2022
arrow
News | Nuclear Imaging

July 27, 2022 — Patients for Safer Nuclear Medicine, a coalition of 29 patient advocacy organizations representing ...

Time July 27, 2022
arrow
News | Radiation Oncology

July 25, 2022 — RaySearch Laboratories AB announces the launch of RayStation* 12A, the latest version of the company’s ...

Time July 25, 2022
arrow
News | PET Imaging

July 20, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 20, 2022
arrow
News | Radiopharmaceuticals and Tracers

July 20, 2022 — -NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time July 20, 2022
arrow
Subscribe Now